Skip to main content
. 2023 May 3;10(20):2300517. doi: 10.1002/advs.202300517

Figure 5.

Figure 5

In vivo therapeutic effects and immune activation of CH‐OD‐SSZ hydrogel. A) Animal experiment outline for the treatment of mice intraperitoneally injected with H22‐luc hepatoma cells. B) In vivo bioluminescence images of H22‐luc hepatoma ascites mice under different treatment conditions. C‐G) Tumor immune microenvironment of ascites was detected by flow cytometry (n = 8 mice per group). (C, D) The expression of CD80 (C) and CD86 (D) in DCs (CD45+CD11c+). (E) The expression of CD86 in TAMs (CD45+CD11b+F4/80+). (F, G) The percentage of CTLs (CD8+IFNγ +, (F)) and Th1 cells (CD4+IFNγ +, (G)) in T cells (CD45+CD3+). *P < 0.05, **P < 0.01, ***P < 0.001 analyzed by one‐way ANOVA.